Morgan Stanley’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.2M Sell
2,481,104
-687,638
-22% -$3.12M ﹤0.01% 3408
2026
Q1
$14.3M Sell
3,168,742
-439,047
-12% -$2.29M ﹤0.01% 3263
2025
Q4
$22.2M Sell
3,607,789
-9,136
-0.3% -$66.2K ﹤0.01% 2843
2025
Q3
$26.2M Sell
3,616,925
-937,155
-21% -$5.56M ﹤0.01% 2626
2025
Q2
$24.2M Buy
4,554,080
+2,939,498
+182% +$17.4M ﹤0.01% 2607
2025
Q1
$14.3M Buy
1,614,582
+329,465
+26% +$3.96M ﹤0.01% 3013
2024
Q4
$17.6M Buy
1,285,117
+404,130
+46% +$7.46M ﹤0.01% 2886
2024
Q3
$24.1M Sell
880,987
-491,650
-36% -$13.3M ﹤0.01% 2611
2024
Q2
$33.6M Sell
1,372,637
-299,116
-18% -$6.56M ﹤0.01% 2136
2024
Q1
$35.6M Buy
1,671,753
+835,846
+100% +$18M ﹤0.01% 2086
2023
Q4
$16M Buy
835,907
+281,255
+51% +$4.87M ﹤0.01% 2905
2023
Q3
$8.9M Sell
554,652
-91,974
-14% -$1.75M ﹤0.01% 3227
2023
Q2
$15M Buy
646,626
+21,224
+3% +$463K ﹤0.01% 2775
2023
Q1
$14.5M Sell
625,402
-271,479
-30% -$5.51M ﹤0.01% 2776
2022
Q4
$13M Buy
896,881
+212,232
+31% +$3.95M ﹤0.01% 2801
2022
Q3
$13.1M Sell
684,649
-33,259
-5% -$763K ﹤0.01% 2675
2022
Q2
$13M Buy
717,908
+140,060
+24% +$2.91M ﹤0.01% 2775
2022
Q1
$14.6M Buy
577,848
+120,611
+26% +$3.09M ﹤0.01% 2451
2021
Q4
$12.6M Sell
457,237
-404,501
-47% -$11.7M ﹤0.01% 2677
2021
Q3
$27.8M Buy
861,738
+7,574
+0.9% +$252K ﹤0.01% 1751
2021
Q2
$26.1M Buy
854,164
+107,760
+14% +$3.11M ﹤0.01% 1877
2021
Q1
$22.7M Sell
746,404
-1,477,464
-66% -$41.9M ﹤0.01% 1790
2020
Q4
$44M Buy
2,223,868
+1,430,509
+180% +$23.1M 0.01% 1179
2020
Q3
$10.3M Sell
793,359
-62,103
-7% -$786K ﹤0.01% 1997
2020
Q2
$9.7M Sell
855,462
-275,784
-24% -$3.92M ﹤0.01% 1995
2020
Q1
$16.2M Sell
1,131,246
-742,039
-40% -$15.7M ﹤0.01% 1431
2019
Q4
$51M Buy
1,873,285
+1,138,223
+155% +$31.3M 0.01% 920
2019
Q3
$21M Buy
735,062
+262,240
+55% +$7.64M 0.01% 1454
2019
Q2
$13.1M Buy
472,822
+354,233
+299% +$10M ﹤0.01% 1871
2019
Q1
$3.94M Sell
118,589
-505,669
-81% -$15.4M ﹤0.01% 2938
2018
Q4
$18.1M Sell
624,258
-113,069
-15% -$4.07M 0.01% 1542
2018
Q3
$33.9M Buy
737,327
+387,692
+111% +$17.2M 0.01% 1235
2018
Q2
$13.1M Sell
349,635
-67,308
-16% -$2.27M ﹤0.01% 2074
2018
Q1
$12.3M Buy
416,943
+1,921
+0.5% +$65K ﹤0.01% 2144
2017
Q4
$14.3M Buy
415,022
+165,645
+66% +$5.59M ﹤0.01% 2029
2017
Q3
$9.02M Buy
249,377
+53,597
+27% +$1.53M ﹤0.01% 2383
2017
Q2
$5.06M Sell
195,780
-73,408
-27% -$1.56M ﹤0.01% 2827
2017
Q1
$5.17M Sell
269,188
-833,566
-76% -$14.8M ﹤0.01% 2833
2016
Q4
$18.4M Sell
1,102,754
-331,419
-23% -$6M 0.01% 1620
2016
Q3
$29.5M Buy
1,434,173
+158,899
+12% +$4.03M 0.01% 1170
2016
Q2
$39M Buy
1,275,274
+622,166
+95% +$21.6M 0.01% 944
2016
Q1
$24.4M Buy
653,108
+38,699
+6% +$1.46M 0.01% 1196
2015
Q4
$26.5M Buy
614,409
+481,702
+363% +$20.4M 0.01% 1201
2015
Q3
$4.97M Sell
132,707
-71,602
-35% -$2.54M ﹤0.01% 2667
2015
Q2
$6.95M Buy
204,309
+30,770
+18% +$1.05M ﹤0.01% 2488
2015
Q1
$6.14M Sell
173,539
-150,111
-46% -$5.37M ﹤0.01% 2555
2014
Q4
$11M Sell
323,650
-78,476
-20% -$2.78M ﹤0.01% 1973
2014
Q3
$15.5M Sell
402,126
-134,759
-25% -$5.03M 0.01% 1637
2014
Q2
$20.9M Sell
536,885
-204,482
-28% -$7.61M 0.01% 1406
2014
Q1
$25.3M Buy
741,367
+3,160
+0.4% +$97.9K 0.01% 1184
2013
Q4
$15.5M Buy
738,207
+197,729
+37% +$5M 0.01% 1566
2013
Q3
$12.7M Sell
540,478
-74,152
-12% -$2.11M 0.01% 1576
2013
Q2
$16.5M Buy
+614,630
New +$17.8M 0.01% 1301

Other funds holding MYGN

Morgan Stanley's MYGN Position: Q2 2026 in Review

Morgan Stanley reduced its Myriad Genetics (MYGN) stake by 22% in Q2 2026, selling an estimated $3.12M and leaving 2,481,104 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Morgan Stanley first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $51M in Q4 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Morgan Stanley held 2,481,104 shares of Myriad Genetics worth $14.2M as of Q2 2026.
  • Morgan Stanley sold 687,638 Myriad Genetics shares in Q2 2026, an estimated $3.12M.
  • Myriad Genetics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3408 holding.
  • Morgan Stanley first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's Myriad Genetics position peaked at $51M in Q4 2019.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.